'Can't say no': Kite Pharma taps Frank Neumann as new head of clinical development

Kite Pharma hit a major landmark in July when it got a second FDA OK, creating the first commercial CAR-T portfolio. But a biotech’s work is never done. Now it’s time to expand — and the Gilead subsidiary has tapped a new global head of clinical development to lead the charge.